case_images: PMC11793988_01
case_images: Preoperative imaging. (a) A contrast-enhanced CT scan of the pelvis reveals a mass localized to the uterus, with no evidence of metastatic involvement (red arrowhead). (b) A T2-weighted MRI of the pelvis demonstrates a tumor confined to the uterine corpus, with an estimated invasion extending beyond 50% of the myometrium (red arrowhead). CT: computed tomography; MRI: magnetic resonance imaging
case_images: cureus-0017-00000076924-i01.jpg
case_images: PMC11793988_01_cureus-0017-00000076924-i01.jpg
case_images: FIG1
case_images: MRI indicated that the tumor was confined to the uterine corpus, with an estimated invasion of more than 50% of the myometrium (Figure 1).
case_images: Postoperative PET-CT imaging one month after primary surgery. (a) FDG uptake is observed diffusely throughout the body. (b) FDG uptake is noted in the left posterior thoracic region. (c) FDG uptake is identified in the left axillary region. (d) FDG uptake is seen in the left buttock region. All subcutaneous metastases were palpable upon physical examination. FDG: 18F-fluorodeoxyglucose; PET-CT: positron emission tomography-computed tomography
case_images: cureus-0017-00000076924-i02.jpg
case_images: PMC11793988_01_cureus-0017-00000076924-i02.jpg
case_images: FIG2
case_images: A PET-CT scan revealed 18F-fluorodeoxyglucose (FDG) uptake in the lungs, liver, multiple subcutaneous regions, and pelvic floor (Figure 2).
case_images: CT images showing response to chemotherapy. The upper row displays pre-treatment images, while the lower row presents post-treatment images following three cycles of paclitaxel and carboplatin. A nearly complete resolution of all metastatic lesions is observed. Red arrows indicate subcutaneous metastases. CT: computed tomography
case_images: cureus-0017-00000076924-i03.jpg
case_images: PMC11793988_01_cureus-0017-00000076924-i03.jpg
case_images: FIG3
case_images: After six cycles of paclitaxel and carboplatin, a CT scan demonstrated an almost complete response to all metastatic lesions (Figure 3).